(Q63834223)

English

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Fulvestrant With or Without AZD6244, a Mitogen-Activated Protein Kinase Kinase (MEK) ½ Inhibitor, in Advanced Stage Breast Cancer Progressing After Aromatase Inhibitor: A Randomized Placebo-Controlled Double-Blind Phase II Trial (English)

0 references

0 references

0 references

August 2010

0 references

end time

December 2012

0 references

number of participants

46

0 references

clinical trial phase

phase II clinical trial

0 references

research site

Ghent University Hospital

0 references

Aarau cantonal Hospital

0 references

Kantonsspital Baden

0 references

Hopitaux universitaires de Genève (HUG), Archives centrales

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

stated in

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.

0 references

Identifiers

ClinicalTrials.gov ID

NCT01160718

0 references

(Q63834223)

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)